Effect of Pioglitazone on Proteinuria in Non-Diabetic Renal Patients: A Self-Control Clinical Trial
| Autor: | Shahrzad Shahidi, Bahram Pakzad, Mozhgan Mortazavi, Shiva Seirafian, Mojtaba Akbari, Abdolamir Atarpour, Alireza Shaygan Nezhad |
|---|---|
| Jazyk: | perština |
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | مجله دانشکده پزشکی اصفهان, Vol 28, Iss 112 (2010) |
| Druh dokumentu: | article |
| ISSN: | 1027-7595 1735-854X |
| Popis: | Background: Proteinuria has independent deleterious effects on the progression of chronic renal disease. The aim of this study was to determine effect of pioglitazone on proteinuria in patients with non-diabetic renal disease. Methods: This was a self-controlled clinical trial study conducted in Al-Zahara Hospital and few private clinics of nephrology in Isfahan. Forty four non-diabetic patients aged 18 and over, who had renal disease and stable proteinuria over 0.5 g in 24 h and body mass index (BMI) lower than 30 kg/m2, were enrolled in the study. Patients were treated by 15 mg of pioglitazone for 4 months. The primary end point was urine protein excretion, measured prior to the study, at the end of 2 and 4 months during treatment as well as 2 months after cessation of pioglitazone. Secondary end points included systolic blood pressure, creatinine, ALT, AST, FBS, BUN and GFR levels. Findings: Mean urine protein excretion was 1088.6 ± 775.6 mg/24 h before treatment; therefore mean urine protein excretion at the end of 4th month was 433.9 ± 406.2 mg/24 h) P 0.01). Conclusion: Considering complications of proteinuria followed by gradual kidney malfunction based on findings of present study, pioglitazone could significantly decrease proteinuria in patients with non-diabetic kidney diseases. Key words: Proteinuria, Pioglitazone, Non-diabetic renal disease, Hypoglycemic agent. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|